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Objectives: Co-treatment of HIV and TB in young children is complicated by limited treatment options and
complex drug–drug interactions. Rifabutin is an alternative to rifampicin for adults receiving a ritonavir-boosted
PI. We aimed to evaluate the short-term safety and pharmacokinetics of rifabutin when given with lopinavir/
ritonavir in children.
Patients and methods: We conducted an open-label study of rifabutin dosed at 5 mg/kg three times a week in HIV-
infected children ≤5 years of age receiving lopinavir/ritonavir. Intensive steady-state pharmacokinetic sampling
was conducted after six doses. The Division of AIDS 2004, clarification 2009, table for grading severity of adverse
events was used to classify drug toxicities. The study was registered with ClinicalTrials.gov, number NCT01259219.
Results: Six children completed the study prior to closure by institutional review boards. The median (range)
AUC0 – 48 of rifabutin was 6.91 (3.52–8.67) mg .h/mL, the median (range) Cmax of rifabutin was 0.39 (0.19–
0.46) mg/mL, the median (range) AUC0 – 48 of 25-O-desacetyl rifabutin was 5.73 (2.85–9.13) mg.h/mL and the
median (range) Cmax of 25-O-desacetyl rifabutin was 0.17 (0.08–0.32) mg/mL. The neutrophil count declined
in all children; two children experienced grade 4 neutropenia, which resolved rapidly without complications.
There was strong correlation between AUC0 – 48 measures and neutrophil counts.
Conclusions: Rifabutin dosed at 5 mg/kg three times per week resulted in lower AUC0 – 48, AUC0 – 24 and Cmax
values for rifabutin and 25-O-desacetyl rifabutin compared with adults receiving 150 mg of rifabutin daily, the
current recommended dose. We observed high rates of severe transient neutropenia, possibly due to immaturity
of CYP3A4 in young children. It remains unclear whether a safe and effective rifabutin dose exists for treatment of
TB in children receiving lopinavir/ritonavir.
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Introduction
TB is the commonest opportunistic infection in HIV-infected chil-
dren, with almost one in three children in South Africa on TB treat-
ment at the time of initiating combination ART (cART).1 While
cART should be initiated as soon as TB treatment is tolerated, ini-
tiation of cART in young children on TB treatment is complicated
by clinically significant drug–drug interactions between rifampicin
and antiretroviral drugs, as well as limited paediatric drug for-
mulations for concomitant TB and HIV treatment. In resource-
poor countries, most adults with HIV/TB coinfection receive a
combination of efavirenz-based cART and rifampicin-based TB
treatment. Efavirenz is not recommended in children ,3 years
of age despite recent FDA approval as there is considerable phar-
macokinetic variability and data are limited.2 For children
,3 years with TB/HIV coinfection, the 2013 WHO guidelines rec-
ommend either a triple NRTI regimen or two NRTIs plus nevirapine
in children co-treated with rifampicin-containing TB therapy.2
While no randomized controlled trials (RCTs) of these regimens
have been performed in young HIV-infected children with active
TB, data from studies in children without active TB suggest
that both of these regimens are suboptimal. Two RCTs have
demonstrated lower virological suppression rates in young chil-
dren without TB when treated with nevirapine- compared with
# The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the
original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
J Antimicrob Chemother 2015; 70: 543–549
doi:10.1093/jac/dku382 Advance Access publication 3 October 2014
543
lopinavir/ritonavir-based cART.3,4 Furthermore, there are concerns
that co-treatment with rifampicin might result in a reduction in
nevirapine concentrations in children.5 The ARROW trial demon-
strated significantly worse long-term viral load suppression rates
in those children who were switched to a triple NRTI regimen
36 weeks after commencing a four-drug regimen consisting of
nevirapine and three NRTIs.6,7
The induction of hepatic and intestinal cytochrome P450 3A4
(CYP3A4) and P-glycoprotein results in inadequate lopinavir
exposure in children when lopinavir/ritonavir is administered at
either standard or double dose together with rifampicin.8 In
South Africa, the recommended cART regimen for children
,3 years who receive concomitant treatment for TB is to add add-
itional ritonavir such that the lopinavir/ritonavir ratio is increased
from 4:1 to 1:1 together with two NRTIs.9 This regimen is also
suboptimal as the short shelf life of ritonavir results in frequent
stock outs and the palatability of ritonavir is poor.
Rifabutin is recommended as an alternative to rifampicin to
treat TB in combination with PI-containing cART in adults and
was added to the WHO essential medicine list in 2009 for treat-
ment of TB in HIV-infected adults treated with ritonavir-boosted
PI-containing cART.10,11 In contrast to rifampicin, rifabutin
induces the activity of CYP3A4 and P-glycoprotein to a limited
extent and does not have clinically significant effects on the con-
centrations of concomitantly administered lopinavir/ritonavir.10,12
However, ritonavir-mediated CYP3A4 inhibition inhibits the
metabolism of both rifabutin and its active metabolite, 25-O-
desacetyl rifabutin and results in a substantial increase in expos-
ure, necessitating a reduction in the dose of rifabutin.12 Because
of concerns of inadequate response associated with rifabutin
dosed at 150 mg three times a week, the recommended dose
of rifabutin in adults receiving concomitant ritonavir-boosted
PI-based cART has recently been increased to 150 mg daily or
300 mg three times a week.13
Safety data for concomitant administration of rifabutin and
lopinavir/ritonavir in HIV-infected individuals in resource-limited
settings are scarce. Haematological toxicities, most commonly
neutropenia and thrombocytopenia, associated with rifabutin
dose and/or coadministration of CYP3A4 inhibitors have been
well described, though it remains unknown whether the occur-
rence of toxicities is associated with specific pharmacokinetic
parameters.14 – 17 While resolution is generally rapid after discon-
tinuation of rifabutin, monitoring of haematological parameters is
recommended. In addition, monitoring for uveitis is required.10
Currently, the major obstacle to the use of rifabutin to treat
TB in young HIV/TB-coinfected children receiving concomitant
lopinavir/ritonavir is the absence of pharmacokinetic and safety
data and no suitable paediatric formulation of rifabutin. We
aimed to determine the optimal dosing strategy, pharmacokinetic
profile and short-term safety of rifabutin when given concomi-
tantly with a lopinavir/ritonavir-containing cART regimen in
HIV-infected children ≤5 years of age in Soweto, South Africa.
Patients and methods
Study design and treatment
We conducted an open-label, adaptive study to determine the short-term
safety and optimal dose of rifabutin when coadministered with lopinavir/
ritonavir in young (age ≤5 years) HIV-infected children residing in a high
TB/HIV burden, resource-limited setting. The optimal dose was defined
as the dose that resulted in a geometric mean AUC0–48 of 4.5–6 mg.h/mL,
in keeping with the levels reported from studies in adults receiving 150 mg
three times a week,17–19 the recommended adult dose at the time of enrol-
ment into the study.20 The initial rifabutin dose was selected based on the
150 mg used thrice weekly in adults adjusted for children based on their
weight using the established scientific framework of an allometric scaling
(clearance and volume having allometric exponents of 0.75 and 1, respect-
ively21). Accordingly, a 10 kg child would be expected to have approximately
twice the clearance (per kilogram of body weight) of an adult, corresponding
to approximately twice the per kilogram dose requirement in children aged
1–5 years. A rifabutin dose of 5 mg/kg three times per week thus was antici-
pated to correspond to the 150 mg three times a week rifabutin dose for
adults when co-treated with lopinavir/ritonavir.12,20
Participating children received a total of six doses of 5 mg/kg rifabutin
(three times a week on Mondays, Wednesdays and Fridays over a 2 week
period). All children took the first dose of rifabutin on a Friday and the final
dose on a Wednesday. The rifabutin suspension was compounded by
research pharmacists using 150 mg Mycobutinw capsules, OraSurew and
Orasweetw.22 Since one anticipates minimal change in lopinavir exposures
with the addition of rifabutin, lopinavir/ritonavir dosages were dosed twice
daily according to the WHO weight bands and not altered during coadmi-
nistration with rifabutin.23 The first and sixth doses of rifabutin were dir-
ectly observed. Parents were telephonically contacted after all other
rifabutin doses to confirm administration according to schedule. In add-
ition, adherence to rifabutin and antiretroviral agents was assessed
using diary cards and weighing of medicine bottles at dispensing and on
return. A full medical history and clinical examination were conducted at
screening, enrolment, the three consecutive pharmacokinetic sampling
days (days 13, 14 and 15) and at the close-out visit, which was conducted
between 2 and 4 weeks after the last dose.
A data and safety monitoring board (DSMB) consisting of two inde-
pendent South African infectious diseases paediatricians and an inde-
pendent US-based pharmacologist was constituted and reviewed all
serious adverse events and any grade 3 or 4 adverse events according
to the NIAID Division of AIDS (DAIDS) 2004, clarification 2009, grading
tables.24 The study protocol mandated that enrolment would be halted
if the DSMB determined that any serious adverse event, grade 3 or 4
adverse event or uveitis was related to rifabutin exposure. In that case,
all pharmacokinetic samples already collected would be analysed and a
DSMB review of all data would be conducted. In addition, an interim ana-
lysis of rifabutin pharmacokinetic parameters was planned after the first
10 children completed pharmacokinetic assessments in order to deter-
mine the final sample size.
The study was approved by the Human Research Ethics Committees of
the University of the Witwatersrand and University of Cape Town and the
Institutional Review Board of the University of North Carolina Chapel Hill.
The study was registered with ClinicalTrials.gov, number NCT01259219.
Written informed consent was obtained from the parents of all participat-
ing children.
Study population
HIV-infected children ≤5 years of age who had successfully completed a
course of therapy for active TB within the past 2–6 weeks and who were
receiving a cART regimen containing lopinavir/ritonavir at the Harriet Shezi
Children’s Clinic in Soweto were invited to participate. The requirement to
have recently successfully completed a course of therapy, defined as com-
pleted a course with resolution of symptoms and signs, was instituted to
reduce the risk that an HIV-infected child with untreated or undiagnosed
active TB would be exposed to rifabutin monotherapy. To reduce potential
risk associated with administration of rifabutin in the absence of direct
benefit, children were excluded if they had a history of symptomatic clin-
ical hepatitis during TB treatment, ALT .2.5× the upper limit of normal
(ULN), bilirubin .1.5× ULN, creatinine .1.1× ULN, haemoglobin ,8 g/dL,
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neutrophil ,1000 cells/mm3, platelets ,125000 cells/mm3, any pre-
existing eye condition at screening or required treatment with another
drug with potential for interaction with rifabutin.
Pharmacokinetic and safety sampling
Blood for safety parameters was drawn for full blood count, white blood
cell differential count, liver function tests, bilirubin, urea, creatinine and
electrolytes at screening and full blood count, white blood cell differential
count and liver function tests at first scheduled pharmacokinetic visit.
Children were screened for symptoms and signs of uveitis at every visit
and were referred for slit lamp examination by an ophthalmologist if
required. Serial blood samples for pharmacokinetic analysis were collected
pre-dose (0 h) and at 2, 4, 9, 24 and 48 h after the observed administration
of the sixth rifabutin dose. Samples were centrifuged at 2600 rpm for
10 min and plasma was extracted and stored at 2708C.
Rifabutin and 25-O-desacetyl rifabutin were analysed with a validated
LC/MS/MS assay. The samples were processed with a protein precipitation
extraction method using 50 mL of plasma and 300 mL of acetonitrile.
Rifaximin was used as an internal standard and was spiked into the pre-
cipitation solvent at a concentration of 100 ng/mL. Gradient chromatog-
raphy was performed on a Phenomenex, Luna 5 mm PFP(2), 100 A, 50
mm×2 mm analytical column, using acetonitrile and 0.1% formic acid
as mobile phase, and was delivered at a flow rate of 500 mL/min. An AB
Sciex API 3200 mass spectrometer was operated at unit resolution
in the multiple reaction monitoring mode, monitoring the transition of
the protonated molecular ions at m/z 847.4 to the product ions at m/z
95.1 for rifabutin, the protonated molecular ions at m/z 805.4 to the prod-
uct ions at m/z 95.1 for 25-O-desacetyl rifabutin and the protonated
molecular ions at m/z 786.3 to the product ions m/z 151.1 for the internal
standard. The accuracies (%Nom) for rifabutin and 25-O-desacetyl rifabu-
tin were between 99.1% and 109.0% at low, medium and high quality
control (QC) levels during interbatch validation. The percentage coefficient
of variation (%CV) for rifabutin and 25-O-desacetyl rifabutin during inter-
batch validation was ,9.2% at low, medium and high QC levels. The
calibration range for rifabutin was between 3.91 ng/mL and 1000 ng/mL
and for 25-O-desacetyl rifabutin the calibration range was between
0.780 ng/mL and 200 ng/mL.
Statistical analysis
Age- and sex-adjusted Z-scores for weight and height were calculated
using WHO 2006 growth references.25 Pharmacokinetic data were ana-
lysed in Stata 12.2 (StataCorp) using non-compartmental methods and
the trapezoid rule to obtain the area under the curve from 0 to 24 h
(AUC0 – 24) and from 0 to 48 h (AUC0 – 48), Cmax, Tmax and elimination half-
life. Pearson correlation coefficients were calculated to assess the strength




Between December 2010 and July 2011, informed consent was
obtained for seven children; six were enrolled and one died of
acute pneumonia prior to the screening visit. The median (range)
age and weight of the children were 27 (10–41) months and
10.6 (8.8–12.2) kg, respectively (Table 1). Three children had a his-
tory of WHO stage IV-defining conditions: two extrapulmonary TB
and one confirmed cytomegalovirus infection without ocular
involvement. Children had been on lopinavir/ritonavir-based cART
for a median of 7 months (range 6–28) and had completed TB
treatment a median of 4 weeks (range 3.9–5.7) prior to the first
dose of rifabutin. The median CD4% at enrolment was 24.9%
(range 15.3%–45.8%). HIV-1 RNA viral load on ART was available
for four children; all had ≤400 copies/mL. All six children received
daily co-trimoxazole prophylaxis according to South African guide-
lines.26 Adherence to rifabutin as assessed by weighing of medicine
Table 1. Baseline demographic and clinical characteristics of children
Child
1 2 3 4 5 6
Age (months) 12 21 29 10 41 33
Weight (kg) 10.1 9.5 11.8 8.8 12.2 11.1
Weight-for-age Z-score 0.9 21.2 21.0 20.8 21.8 21.9
Height-for-age Z-score 20.1 22.3 23.1 22.4 22.6 21.3
WHO stage 3 3 4 4 4 3
Prior WHO AIDS condition PTB PTB EPTB CMV EPTB PTB
CD4% 15.3 24.0 24.9 NA 29.5 45.8
CD4 count (cells/mm3) 1004 1084 1695 NA 1108 982
Viral load (copies/mL) 400 149 NA NA ,400 190
Haemoglobin (g/dL) 12.6 11.9 10.3 12.0 10.9 11.8
White cell count (109/L) 13.2 11.6 10.3 10.5 16.9 5.3
ANC (109/L) 1.8 1.8 2.7 2.0 8.6 1.5
Platelets (1012/L) 451 333 627 385 330 401
ALT (U/L) 19 26 18 20 43 22
ART drugs in addition to LPV/r d4T+3TC 3TC+ABC 3TC+ABC 3TC+ABC d4T+3TC d4T+3TC
Months on LPV/r-based ART 7 6 6 7 28 19
Time since end of TB treatment (weeks) 5.7 3.9 4.3 4.4 4.4 4.1
PTB, pulmonary TB; EPTB, extrapulmonary TB; CMV, cytomegalovirus; NA, not available; d4T, stavudine; 3TC, lamivudine; ABC, abacavir; LPV/r, lopinavir/ritonavir.
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containers was excellent with adherence ranging between 98%
and 110% in the five children for whom this could be assessed.
Pharmacokinetics of rifabutin
All children had measurable rifabutin concentrations at all time-
points, but there was substantial interindividual variation despite
uniform dosing (Table 2). The median AUC0 – 48 of rifabutin was
6.91 mg.h/mL, ranging from 3.52 to 8.67 mg.h/mL. Only one child
had a rifabutin AUC0–48 below the target range of 4.5–6.0 mg.h/mL.
The median rifabutin Cmax was 0.385 mg/mL, ranging from 0.19
to 0.46 mg/mL. One of the six children had a Cmax .0.45 mg/mL.
The rifabutin half-life was 16.0 h (range 10.9 –38.6). Time of
Cmax indicated delayed absorption in child 1.
Pharmacokinetics of 25-O-desacetyl rifabutin
All children had measurable 25-O-desacetyl rifabutin concentra-
tions at all timepoints (Table 2). The median AUC0 – 48 of
25-O-desacetyl rifabutin was 5.73 mg.h/mL (range 2.9–9.1). The
median 25-O-desacetyl rifabutin Cmax was 0.17 mg/mL. The half-
life of 25-O-desacetyl rifabutin was 36.2 h (range 11.9–55.0).
Combined rifabutin and 25-O-desacetyl rifabutin
pharmacokinetic parameters
The median AUC0–48 and Cmax ratios of 25-O-desacetyl rifabutin to
rifabutin were 0.80 (range 0.70–1.24) and 0.49 (range 0.38–0.72),
respectively. The median combined AUC0 – 48 for rifabutin plus
25-O-desacetyl rifabutin was 12.99 mg.h/mL (range 6.36–16.55).
Adverse events
The ANC decreased in all six children. Two children developed grade
4 neutropenia, one grade 2 neutropenia and one grade 1 neutro-
penia when graded according to the DAIDS 2004, clarification
August 2009, table (Table 3).24 Both of the grade 4 neutropenias
resolved to grade 1 without sequelae, 2 and 6 days after cessation
of drug exposure. Apart from one child who had an intercurrent
infection, no other potential causes for decline in ANC were identi-
fied. When neutrophil counts were graded according to the
pre-2004 grading table, there were no grade 4 events, one grade
3, one grade 2 and two grade 1 neutropenias (Table 3).27
The median platelet count decreased from 393000 cells/mm3
(range 330000–627000) to 260000 cells/mm3 (range 130000–
493000). None of the six children developed elevated liver
enzymes, uveitis, myalgia, arthralgia or gastrointestinal symptoms.
Correlation between ANC and pharmacokinetic
parameters
When excluding the one outlier (child with an elevated baseline ANC
of 8600 cells/mm3 and who had had an intercurrent illness and
whose ANC therefore could be expected to change substantially in
the time period of interest independent of rifabutin exposure),
there was a strong correlation between pharmacokinetic para-
meters and ANC measured during rifabutin administration
(Figure 1a–c): r¼20.85 (P¼0.07) for correlation between rifabutin
AUC0 – 48 and ANC; r¼20.94 (P¼0.02) for correlation between
AUC0 – 48 of the metabolite 25-O-desacetyl rifabutin and ANC;
and r¼20.96 (P¼0.01) for correlation between the combined
AUC0 – 48 of rifabutin and its metabolite 25-O-desacetyl rifabutin
and ANC. The correlation between Cmax and ANC was r¼20.67
(P¼0.21) for rifabutin Cmax and r¼20.90 (P¼0.04) for
25-O-desacetyl rifabutin Cmax. There was no correlation between
any of these pharmacokinetic parameters and ANC when the outlier
was not excluded.
Table 2. Rifabutin and 25-O-desacetyl rifabutin pharmacokinetic











Child 1 6.11 7.31 10.9 0.45 9
Child 2 5.77 8.03 14.3 0.35 4
Child 3 2.33 3.52 37.1 0.19 2
Child 4 4.96 6.49 17.4 0.46 4
Child 5 3.46 5.67 38.6 0.21 2
Child 6 6.29 8.67 14.6 0.42 2
median 5.36 6.91 16.0 0.39 3
25-O-desacetyl rifabutin
Child 1 5.95 9.13 21.0 0.32 9
Child 2 3.40 6.01 39.8 0.17 9
Child 3 1.62 2.85 55.0 0.08 4
Child 4 3.29 5.46 32.6 0.17 9
Child 5 2.19 3.95 54.2 0.10 4
Child 6 4.61 6.80 11.9 0.23 4
median 3.34 5.73 36.2 0.17 7














6 56 5.00 1540 450 4 2
1 50 4.95 1810 330 4 3
2 48 5.05 1800 770 2 1
4 44 5.00 1960 1160 1 1
3 60 5.08 2690 1490 — —
5 62 5.05 8600 3270 — —
aTaken on first pharmacokinetic day (day 13).
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Review of study by DSMB, ethics committees and
funding agency
Per protocol DSMB reviews were conducted after the first and sixth
children had grade 4 neutropenia. The DSMB classified the first
case as unrelated to rifabutin as the child had an intercurrent
infection at the time and the second case as potentially related
to rifabutin. The DSMB and Human Research Ethics Committees
of the University of the Witwatersrand and Cape Town approved
an amended protocol with a reduced rifabutin dose (from 5 to
3 mg/kg three times a week), an additional safety visit after
the third dose of rifabutin and a switch to the DAIDS 1994 grading
tables to address the issue of ethnic neutropenia. The Institutional
Review Board of the University of North Carolina determined that
the study required approval under 45 CFR 46.407 because of
greater than minimal risk without direct benefit. The study was
stopped when the funding agency decided not to pursue the
407 process.
Discussion
In this study, we found that rifabutin dosed at 5 mg/kg three
times a week together with a lopinavir/ritonavir-containing cART
regimen in young (≤5 years) children resulted in generally higher
AUC0 – 48, AUC0 – 24 and Cmax values for rifabutin and 25-O-desace-
tyl rifabutin compared with adults receiving 150 mg of rifabutin
three times a week,18,19 though lower than the values associated
with the more recent recommendations of 150 mg of rifabutin
daily.19,28 High rates of severe neutropenia were observed and
values for rifabutin and 25-O-desacetyl rifabutin AUC were
strongly correlated with low neutrophil counts during rifabutin
administration.
Despite the dose adjustments made to account for expected
differences in clearance between children and adults,29 the
median rifabutin AUC0 – 24, AUC0 – 48 and Cmax parameters
observed in these young children were higher than those reported
in a study of 10 adults in the USA receiving 150 mg of rifabutin
three times a week in combination with lopinavir/ritonavir.18 In
these adults, Boulanger et al.18 observed a median rifabutin
Cmax of 0.23 (0.04–0.32) mg/mL and AUC0 – 48 of 4.42 (0.96 –
7.48) mg . h/mL, lower than the median Cmax of 0.39 (0.19 –
0.46) mg/mL and AUC0 – 48 of 6.91 (3.52–8.67) mg.h/mL observed
in our paediatric study. In contrast, a study of 13 Vietnamese
adults receiving 150 mg of rifabutin thrice weekly in combina-
tion with lopinavir/ritonavir observed higher median values for
Cmax [0.54 (0.06 –0.96) mg/mL] and AUC0 – 48 [7.34 (1.43 –
10.90) mg.h/mL] than those observed in our study.28
The rifabutin AUC0 – 48 in our study participants receiving rifabu-
tin three times per week were not surprisingly substantially lower
than those in both Vietnamese (14.58 mg .h/mL) and South
African (9.53 mg.h/mL) adults when dosed at 150 mg of rifabutin
daily, the current recommended dose in combination with lopina-
vir/ritonavir.19,28
We also found high AUC0 – 48 values for the active metabolite
25-O-desacetyl rifabutin [5.73 (2.85 –9.13) mg . h/mL], higher
than those observed in US adults [2.70 (1.39–4.23) mg .h/mL]
and Vietnamese adults [3.81 (0.87–7.63) mg.h/mL] when dosed
at 150 mg three times a week. This is consistent with potent
inhibition of CYP3A4 by ritonavir and the immaturity of the
CYP3A4 enzyme in young infants.29
The decline in ANC in all children soon after administration of
rifabutin, with two of six children experiencing severe neutropenia
after six doses of rifabutin, is cause for concern, even if the neutro-
penia resolved rapidly and without sequelae after withdrawal of
rifabutin. While neutropenia has been described in adults receiv-
ing rifabutin, the rate observed in this group of young children was
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Figure 1. Correlation between ANC on day 13 of rifabutin exposure and (a)
rifabutin AUC0 – 48, (b) 25-O-desacetyl rifabutin AUC0 – 48 and (c) combined
rifabutin and 25-O-desacetyl rifabutin AUC0 – 48.
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higher than expected. In the study of Vietnamese adults, only 1 in
12 adults developed a grade 3 neutropenia and no grade 4 neu-
tropenia was observed. Similarly, in the study of US adults, two
patients developed grade 2 neutropenia and no grade 3 or 4 neu-
tropenia was observed. The strong correlation between the ANC
under rifabutin and high plasma concentration of both rifabutin
and its metabolite in our study suggest that the neutropenia
observed may be the consequence of immaturity of CYP3A4 in
these young children. It is important to note however that when
1994 DAIDS grading tables were applied the grades of neutro-
penia experienced in our study were less severe, supporting the
need for population-specific grading tables for neutrophil counts
to accommodate relative ethnic neutropenia.30 – 32
In conclusion, the 5 mg/kg dose of rifabutin resulted in lower
rifabutin and 25-O-desacetyl rifabutin exposures in young children
than those obtained in adults dosed at 150 mg of rifabutin daily,
the current recommended dose for co-treatment with a ritonavir-
boosted PI. The high interindividual variability in plasma concentra-
tions, the high rates of neutropenia and the strong association
between rifabutin and 25-O-desacetyl rifabutin plasma concentra-
tions and neutrophil count suggest that it will be difficult to identify
a safe and effective dose of rifabutin for young children in need of
concomitant treatment with lopinavir/ritonavir.
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